Our in vivo and in vitro experiments demonstrated that apelin-13 significantly upregulates BDNF-AS m6A methylation levels in a dose-dependent manner within AD models, resulting in a subsequent downregulation of BDNF-AS expression. Here, APLN is linked to Alzheimer disease.